December 2024
First Investment Date
Fund
Indaco Bio and Indaco Bio Parallel
HQ
Perugia, Italy
Sector
Biotech and Pharma
Website
Investment Status
Ongoing
Tes Pharma is a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in metabolic, renal diseases and oncology. Tes Pharma’s clinically validated drug discovery engine generates rationally designed drug candidates for novel targets. Tes Pharma has a long-standing partnership with Intercept/Alfasigma for the discovery and development of bile acid derivatives for the treatment of metabolic diseases. INT-787 is undergoing Phase 2 clinical studies for the treatment of severe alcohol hepatitis. TES-AKI-01 and TES-ONC-07 are two first-in-class small molecules for the treatment of acute kidney injury and for cancer immunotherapy, respectively, entering IND-enabling studies. Tes Pharma has an undisclosed pipeline of additional projects in the early phase of drug discovery.
Indaco Venture Partners has joined the Series A Financing previously led by XGEN Venture, bringing the total raise to € 15 million. The financing supports the development of TES-AKI-01 and the additional pipeline programs for the treatment of metabolic and oncological diseases.
Indaco Bio Fund and Indaco Bio Parallel Fund have invested into Tes Pharma SRL in December 2024.
Related Projects
